Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN

Murphy Andrew J sold 5,011 Regeneron Pharmaceuticals, Inc. shares (Form 4)

Traded Nov 16 to Nov 17, 2026 · Filed Nov 18, 2026

From Nov 16 to Nov 17, 2026, Murphy Andrew J (Co-Chief Scientific Officer) sold 5,011 Regeneron Pharmaceuticals, Inc. shares at an average US$957.76 for US$4.8M under a trading plan, leaving 46,779 shares. Filed Nov 18, 2026 (Form 4).

Sold
5,011 shares
Price
US$957.76 average (US$949.69 to US$964.36)
Value
US$4.8M
Holding after
46,779 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Co-Chief Scientific Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 16, 2026Common StockOption exercise17,000US$381.9263,779Direct
Nov 16, 2026Common StockShares withheld for tax11,989US$960.0251,790Direct
Nov 17, 2026Common StockSale93US$949.6951,697Direct
Nov 17, 2026Common StockSale74US$950.6151,623Direct
Nov 17, 2026Common StockSale298US$951.7551,325Direct
Nov 17, 2026Common StockSale220US$952.7551,105Direct
Nov 17, 2026Common StockSale671US$953.6950,434Direct
Nov 17, 2026Common StockSale313US$954.4550,121Direct
Nov 17, 2026Common StockSale313US$955.4849,808Direct
Nov 17, 2026Common StockSale346US$956.7049,462Direct
Nov 17, 2026Common StockSale202US$957.5349,260Direct
Nov 17, 2026Common StockSale244US$958.2749,016Direct
Nov 17, 2026Common StockSale506US$959.4548,510Direct
Nov 17, 2026Common StockSale257US$960.6548,253Direct
Nov 17, 2026Common StockSale584US$961.4547,669Direct
Nov 17, 2026Common StockSale295US$962.7047,374Direct
Nov 17, 2026Common StockSale255US$963.6047,119Direct
Nov 17, 2026Common StockSale340US$964.3646,779Direct

Source

Download original · View original at SEC

Related